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ABSTRACT
Background: There are several methods to promote informed decision 
making before participating in a screening program. This research aimed to 
analyze the content of official written information on breast cancer screening 
programs.  
Methods: A descriptive study was performed. After a literature review, we 
drew up a checklist of the information needed to make decisions about partici-
pation in mammography screening programs. Various types of official written 
information on mammography screening used in Spain in 2016 were analyzed 
by two independent researchers. The inter-rater agreement was assessed and 
disagreements were resolved by consensus. Absolute and relative frequencies 
were calculated for each item. 
Results: We reviewed 8 invitation and 14 appointment letters, 12 leaflets, 
8 brochures and 14 websites, from 18 breast cancer screening programs. The 
information provided was found to vary considerably between programs. Only 
a third underlined that participation was voluntary; 8 (44.4%) offered informa-
tion on what breast cancer is and 7 (38.9%) on the cumulative risk of develo-
ping the disease; and 15 (83.3%) explained the objectives of the program and 
14 (77.8%) what mammography is. The following benefits of screening were 
mentioned: less invasive treatment by 14 programs (77.8%), longer survival by 
12 (66.7%) and lower specific mortality by 10 (55.6%). Most of the programs 
did not, however, mention the possibility of false positives (27.8%) or false 
negatives (38.9%), while only 7 (38.9%) mentioned the possibility of over-
diagnosis and 6 (33.3%) of overtreatment.
Conclusions: The information provided varies considerably between 
breast cancer screening programs and is generally insufficient for informed 
decision-making.
Key words: Health Communication, Information services, Health Litera-
cy, Mammography, Secondary prevention, Breast cancer, screening, Decision 
making, Use of scientific information in health decision making.
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RESUMEN
Contenido de los documentos informativos dirigidos 
a las mujeres sobre el cribado de cáncer de mama en 
España.
Fundamentos: Existen diversos métodos para facilitar la toma de deci-
siones informada antes de acudir a un programa de cribado. El objetivo de 
este trabajo fue analizar la información de los documentos oficiales sobre los 
programas de cribado de cáncer de mama (PCCM).
Métodos: Estudio descriptivo. Análisis del contenido de los documentos 
informativos de los PCCM vigentes en España en 2016. Se elaboró una lista 
de comprobación con la información necesaria para la toma de decisiones. Dos 
investigadores revisaron independientemente los documentos. Se comprobó la 
concordancia interinvestigador y se resolvieron por consenso las discrepan-
cias. Se calcularon las frecuencias absolutas y relativas de cada ítem. 
Resultados: : Se revisaron 8 cartas de invitación a participar y 14 de ci-
tación, 12 dípticos o trípticos, 8 folletos y 14 webs, procedentes de 18 PCCM. 
La información resultó ser muy dispar según cada programa. 8 programas 
(44,4%) informaban sobre qué es el cáncer de mama y 7 (38,9%) sobre el 
riesgo acumulado de desarrollarlo. 15 (83,3%) explicaban los objetivos del 
PCCM y 14 (77,8%) en qué consiste una mamografía. 14 programas (77,8%) 
presentaban como beneficios el cribado los tratamientos menos invasivos, 12 
el aumento de la supervivencia (66,7%) y 10 la disminución de la mortali-
dad específica (55,6%). La mayoría de los programas no informaban sobre 
la posibilidad de falsos positivos (27,8%) o falsos negativos (38,9%). Sólo 
7 (38,9%) mencionaban la posibilidad de sobrediagnóstico y 6 (33,3%) de 
sobretratamiento. 
Conclusiones: La información que facilitan los diferentes PCCM es varia-
ble y no contiene información suficiente para la toma de decisiones informada.
Palabras clave: Comunicación en Salud, Servicios de información, Al-
fabetización en Salud, Mamografía, Prevención secundaria, Cáncer de mama, 
Cribado, Toma de Decisiones, Uso de información científica en la toma de 
decisiones en salud.
Suggested citation: Ballesteros-Peña S, Gavilán-Moral E. 
Content Of Official Written Information For Women On 
Breast Cancer Screening In Spain. Rev Esp Salud Públi-
ca.2018;92: October 29 e201810076.
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INTRODUCTION
Breast cancer screening programs (BC-
SPs) are based on performing diagnostic 
tests (mammograms) on apparently healthy 
women with the aim of distinguishing those 
who are likely to have breast cancer from 
those who are not likely not to. This is se-
condary prevention measure, the goals of 
which include reducing the number of in-
dividuals in whom precancerous lesions 
are detected who go on to develop invasive 
disease, as well as avoiding early mortality 
associated with breast cancer and in general 
improving the prognosis and quality of life 
of individuals with the disease(1).
Breast cancer screening programs do, 
however, have some disadvantages. For 
example, it has been argued that, as well as 
the potential adverse effects associated with 
diagnostic tests and treatment, individuals in 
whom early detection does not improve their 
prognosis suffer a longer period of morbidi-
ty due to early diagnosis(2). In fact, the grea-
test controversy lies in the possibility that 
the detection of abnormalities of unknown 
prognosis or precursor, non-progressive le-
sions may lead to overdiagnosis and hence 
overtreatment(3), not to mention the potential 
negative psychosocial and emotional effects 
of a false positive on an asymptomatic wo-
man(4). Although BCSPs are generally still 
recommended, all these disadvantages have 
fueled debate about the balance between be-
nefits and risks of this and other programs 
for the early detection of cancer(5,6), to the 
point that France and Switzerland are rede-
signing them or even considering stopping 
them(7,8).
In Spain, population BCSPs are run based 
on performing a mammogram every other 
year,  focused in most autonomous regions 
on women aged 50 to 69 years old(9). In or-
der to recruit participants, the BCSPs send 
a personalized letter accompanied, in many 
cases, by written information on the program 
in the form of a leaflet. Additionally, public 
organizations offer users other materials, in 
paper or electronic formats (brochures or 
websites), in order to support informed de-
cision making concerning whether or not to 
attend preventative check-ups.
In 2010, the ddiscussion paper working 
group on population screening of the Spa-
nish Public Health Committee drafted a fra-
mework document on population screening 
which recognized the need for informed 
decision making in the implementation of 
population screening programs. For this rea-
son, to enable decisions to be informed, it 
was stated that people should have access to 
adequate, high quality, relevant, reliable and 
easy-to-understand information(10). Additio-
nally, this information should be based on 
the best available scientific evidence and 
balanced in relation to the presentation of 
benefits and risks(11).
Earlier, in 2007, a report published in 
Spain concluded that leaflets were one of 
the most efficient ways of providing the 
information necessary to support informed 
decision making by potential participants 
in BCSPs(12). This report also indicated the 
basic information that should be included in 
such leaflets, namely, information about the 
disease itself (breast cancer), the screening 
program, the target population, the scree-
ning interval, the screening test (its nature, 
aim, procedure, validity, benefits, risks and 
results), tests for confirming the diagnosis, 
treatment and how to obtain further infor-
mation. Nevertheless, comparative analysis 
of the official written information issued by 
the BCSPs across Spanish regions yielded 
disappointing results: at that time, not all 
the regions offered information leaflets on 
their BCSPs, and in the case of those that 
did, they provided limited information on 
the risks of screening.
A decade after this report, the objective of 
our study was to analyze the content of offi-
cial written information available to women 
on BCSPs in Spain to facilitate informed de-
cision making.
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MATERIALS AND METHODS
Study material: the units of analysis were 
the official written materials available in the 
first 6 months of 2016 from various diffe-
rent programs for early diagnosis, produced 
by the regional or provincial departments of 
health, focused on women eligible for mam-
mograms under the BCSPs.
In order to obtain these written materials, 
we first contacted the people leading the BC-
SPs, requesting information on the program’s 
recruitment procedure and copies of written 
information for women used in the current 
campaign, such as invitation letters (introdu-
cing the program and inviting women to par-
ticipate in the screening), and appointment 
letters (giving users appointments for a mam-
mogram specifying the date and time) sent to 
the homes of women eligible for screening, 
information leaflets/brochures and websites. 
If no answer was received after a second re-
quest, we contacted healthcare organizations 
or individual health professionals in corres-
ponding regions requesting the information 
and materials of interest. In parallel, we re-
viewed the information available on the offi-
cial websites of the screening programs or 
departments of health. We excluded website 
content that was not intended for the target 
population.
Content analysis. To analyze the content 
of the materials, we drew up a checklist, 
by consensus among researchers, of the ty-
pes of information considered essential for 
informed decision making about screening 
mammograms (Table 1), based on the topics 
covered in similar studies(12,13,14,15,16).
Prior to gathering data, we piloted the 
tool by analyzing the materials from the 
programs that provided the greatest volume 
and variety of information (those of Anda-
lusia and Baleares), seeking to determine 
whether any of the checklist items might be 
found confusing or ambiguous. Doubts and 
disagreements were assessed and discussed 
among researchers and we also sought the 
opinion of external professionals, until a fi-
nal checklist was agreed.
Data processing and statistical analysis: 
Two researchers independently reviewed all 
the study material to assess, overall, whether 
each of the types of content referred to in 
the checklist items items was or was not 
included. The final level of agreement bet-
ween the two reviewers was assessed using 
Cohen´s kappa coefficient and the corres-
ponding 95% confidence intervals (95% CI), 
finding a very high level of overall agree-
ment (0.83%, 95% CI 0.80-0.86; p<0.001). 
Disagreements were discussed and resolved 
by consensus after reviewing the informative 
materials.
For the descriptive analysis of data, abso-
lute and relative frequencies were calculated 
for each of the items studied.
RESULTS
Characteristics of the study material and 
overall results. We reviewed a total of 56 
informative materials (Table 2) offered by 
18 BCSPs. We assessed at least one for-
mat for delivering the information for each 
program. The most studied format was the 
appointment letter (77.8%) followed by we-
bsites (72.2%). 
Four programs (those of Asturias, Casti-
lla La Mancha and Valencia regions and the 
Barcelona Public Health Agency, hereon 
“Barcelona”) provided information on 60% 
or more of the items of the questionnai-
re, while eight programs (Aragón, Castilla 
y León, Extremadura, Canarias, La Rioja, 
Murcia, Navarre  and the Basque Country) 
covered less than 40% of the items. Four 
programs (Asturias, Barcelona, Castilla La 
Mancha and the Balearic Islands) included 
a pictogram summarizing the benefits and 
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risks of screening.
General information on breast cancer (Table 
3). The majority of the BCSPs provided qua-
litative or quantitative information on the inci-
dence of breast cancer and listed associated risk 
factors, and almost half gave information about 
what breast cancer is and its symptoms. Never-
theless, the cumulative risk of developing the 
disease, its natural history and prognosis and 
preventative lifestyles were less often covered, 
and none of the BCSPs provided estimates of 
the lifetime cumulative risk of death due to 
breast cancer. 
Four programs (Extremadura, Canarias, La 
Rioja and Navarre) did not provide informa-
tion related to any items in this domain. Three 
 Table  1
Information considered essential for informed decision making about screening mammo-
grams
Domain Items
Breast cancer
• What the disease is
• Risk factors
• Measures to prevent cancer
• Warning signs and symptoms
• Natural history of the disease
• Incidence and/or prevalence
• Estimated lifetime cumulative risk of developing or dying of the disease
• Quantitative data on prognosis (mortality, survival and cure rates)
General 
information 
on screening: 
program 
objectives and 
characteristics; 
and organi-
zation and 
logistics
• Program objectives
• What early diagnosis is
• What a screening program is
• What a mammogram involves
• Target population
• Eligible age range
• Mention of women outside this age range or at higher risk
• Screening intervals
• What to do if symptoms develop during this interval
• Information on breast self-examination
• Pictograms or infographics
• Information on appointments  (where and when) and how to change them
User rigths
• Participation being optional and free
• Confidentiality
• Clarification of the handling of personal data
• Mention of controversies about the screening and the risks and benefits it entails
Impact of 
screening 
programs
• Benefits (possibility of early or less invasive treatment, mention or quantification of the increase 
in survival and relative or absolute reduction in the risk of death) 
• Risks (mention of possibility and rates of overdiagnosis, overtreatment and false positives and 
negatives; effects of radiation; discomfort or pain associated with the mammogram)
• Strategies to minimize emotional distress (mention of the fact most tests are negative; informa-
tion to reduce concerns associated with confirmatory tests, anxiety about results and fear of cancer 
itself; mention of the availability of effective treatments) 
Confirmatory 
tests
• Mention of the possibility of needing confirmatory tests or reasons why they may be necessary
• Percentage of women called for confirmatory tests
• Identification and description of confirmatory tests, reasons for doing them and potential com-
plications
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 Table  2
Range of types of material analyzed for each breast cancer screening program 
BCSP Invitation letter Appointmnt letter Leaflet Brochure Websites
AR X X X X
AS X X
CN X X X X
CB X X
CM X X X
CL X X X
CT (CIO) X X X
B (BPHA) X
EX X X X X X
GA X
IB X X X
RI X X X X
MD X X X
MC X X X
NC X X
PV X X X
VC X X X
TOTAL 
n (%): 8 (44.4%) 14 (77.8%) 10 (55.5%) 8 (44.4%) 13 (72.2%)
AN: Andalusia; AR: Aragon; AS: Asturias; ASPB: Agencia Salut Pública Barcelona; B: Barcelona; BCSP: 
Breast cancer screening program; BPHA: Barcelona Public Health Agency; CN: Canarias; CB: Cantabria; CIO: 
Catalan Institute of Oncology; CM: Castilla La Mancha; CL: Castilla y León; CT: Catalonia; EX: Extremadura; 
GA: Galicia; IB: Balearic Islands; RI: La Rioja; MD: Madrid; MC: Murcia; NC: Navarre; PV: Basque Country; 
VC: Valencia.
programs (Castilla y León, Castilla La Man-
cha and Valencia) encouraged breast self-
examination or sought to teach women how 
to do it, while two (Asturias and Barcelona) 
discouraged the practice.
General information on the screening 
programs:
- Program objectives and characteristics 
(Table 4). The majority of the BCSPs listed 
the objectives of the screening program and 
what early diagnosis means, but only a few 
explained why healthy women are invited 
to participate. Further, most of the programs 
described what mammograms involve and 
what to do in the event of noticing symp-
toms in the interval between screening tests.
- Program organization and logistics. All the 
programs clearly identified the organization 
running the campaign, and the majority 
gave an adequate amount of information on 
how to contact the people responsible for 
the program, the date of the appointment 
and where to go, how to request or change 
an appointment, the documents to provide, 
Ballesteros-Peña et al.
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how to prepare oneself for a mammogram 
and how to find out the results of the test. 
Only one autonomous region (Castilla La 
Mancha) underlined the need to sign an infor-
med consent form before the test. 
User rights: Only a third of the programs 
recognized that participation in the screening 
program was voluntary. The majority of the 
programs (77.8%) indicated that the test was 
free of charge but few (11.1%) specified that 
it was confidential or how personal data were 
managed (22.2%). The majority did not men-
tion that there is controversy about screening 
(11.1%), although 44.4% explicitly recogni-
zed the presence of both benefits and risks.
Impact of screening programs:
- Benefits of screening (Table 5). Two BC-
SPs (Aragón and Extremadura) did not give 
any information on the benefits of screening. 
Only three programs (Asturias, Barcelona 
and Valencia) gave some information on re-
ductions in mortality risk thanks to screening.
- Disadvantages and risks of screening (Ta-
ble 5). Seven programs provided information 
on the risk of overdiagnosis, although none of 
them quantified this risk, while six noted the 
risk of overtreatment associated with scree-
ning. Two programs (Navarre  and the Basque 
Country) did not mention any of disadvanta-
ges or risks of screening. The majority did 
not properly describe the rates of false posi-
tives and negatives associated with the test, 
although they mentioned that women might 
find the test uncomfortable.
- Minimization of emotional distress. Two 
thirds of the programs analyzed indicated that 
the majority of screening tests conducted are 
negative and half of the programs sought to 
reduce anxiety concerning the results. Only 
22.2% of the programs, however, mentioned 
the availability of effective treatments for 
breast cancer, while a third sought to provide 
data to reduce the fear of cancer. Four pro-
grams did not provide any information related 
to seeking to minimize the emotional distress 
associated with breast cancer screening.  
Confirmatory tests (Table 6). The majority of 
programs mentioned the possibility of being 
called for further tests to confirm mammogra-
phy findings, while less than half set out the 
reasons for undergoing these additional tests 
or the probability of this happening. One in 
two programs mentioned all the types of tests 
that might be offered, but very few provided 
further details, explained why they might be 
necessary or provided information about any 
disadvantages or potential complications. 
Three programs (Aragon, Extremadura and 
Murcia) did not provide any information on 
confirmatory tests.
DISCUSSION
Although there is notably wide variety in 
the format and quality of the official informa-
tion offered to women through the different 
BCSPs in Spain, in general, the contents tend 
to place emphasis on the benefits of screening 
mammograms at the expense of the risks, with 
a significant lack of information about current 
areas of controversy and and user rights, as 
well as little to address the emotional distress 
associated with screening or concerning con-
firmatory tests. Additionally, around half of 
the BCSPs did not provide brochures, despite 
the fact that they may be able to provide more 
comprehensive information than leaflets.
 In Spain, no other studies have recently 
analyzed and compared the official informa-
tion provided by different BCSPs. The only 
study available before ours was conducted by 
Queiro et al. more than a decade ago(12). Our 
findings suggest that the situation has impro-
ved in all areas since then, though unevenly: 
there is moderately more information on the 
risks of screening (for example, the percen-
tage of programs mentioning the possibility 
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of overdiagnosis having grown from 0% to 
38.9% of the BCSPs) and on the objectives 
and characteristics of the program (the per-
centage explaining what early detection is 
having increased from 16.6% to 66.6%); only 
marginally more information about confirma-
tory tests and the benefits of screening; and 
hardly any improvement in terms of the in-
formation addressing emotional distress. Ne-
vertheless, the results of our study and that 
of Queiro are not directly comparable given 
that they have been conducted using different 
assessment instruments. In our case, we have 
included items that we considered important 
for informed decision making, and which 
have been indicated in recent studies(13,14,15,16), 
such as information concerning potential 
complications associated with confirmatory 
tests, the presentation of absolute numbers 
and the use of pictograms (graphical repre-
sentation with greater descriptive and expla-
natory power than text). Despite the qualitati-
ve leap observed in Spain, especially in some 
BCSPs, we consider that the information 
provided remains incomplete and that quite a 
high percentage of the programs do not en-
courage women to take informed decisions.
 The situation in neighboring countries is 
not markedly better than in Spain. Given the 
high variability between published studies 
in the systems for collecting the informati-
ve material provided in screening programs 
and analyzing its content, it is not possible 
to make direct quantitative comparisons, but 
we can appreciate trends that seem to follow 
similar patterns. In countries such as Italy(17) 
and Finland(18), it seems that adequate infor-
mation is provided on the objectives, proce-
dures and advantages of screening, but not on 
risks and disadvantages. A high variability in 
format and content, a lack of information on 
areas that are key to enabling informed de-
cision making and a tendency to present the 
benefits in more detail than the disadvantages 
and risks of screening, as found in our study, 
are issues that are common to various com-
parisons conducted in recent years interna-
tionally(16,19). A recent study was published in 
Italy comparing the information provided to 
users in 2001 and 2014. As in our study, the 
authors observed a slight improvement regar-
ding information on the risk of overdiagno-
sis and of false positives and negatives, but 
pointed out that the information is still far 
from what could be considered balanced(19). 
Other authors go as far as suggesting that the 
bias that tends to be systematically observed 
in all the studies reflects a clear prescriptive 
intent, in the sense that it encourages indivi-
duals to participate in screening, indicating 
that healthcare organizations are worried 
about providing information that could have 
a negative impact on coverage(18). Neverthe-
less, a clinical trial conducted in Spain found 
that providing users with balanced informa-
tion did not seem to influence whether they 
decided to participate in the early detection 
program(20).
In Spain, the percentage of women with a 
reasonable level of knowledge about scree-
ning is very low (being estimated to be 
around 8.4% in our setting)(21). On the other 
hand, the information available to users is, 
in general, incomplete, given that it tends to 
exaggerate the risk of cancer and overesti-
mate the benefits of early detection(22). Given 
this, it seems clear that more effort should be 
made to provide individuals with more balan-
ced and complete information that increases 
users’ knowledge and helps society adopt a 
more realistic view of the real usefulness of 
screening. 
When women receive more complete in-
formation, their level of knowledge grows, 
but the effect varies considerably with the 
format. For example, using brochures rather 
than more limited formats, such as leaflets, 
women gain knowledge, but only a modest 
amount and in some areas, namely, those 
which are the easiest to understand(23). Nota-
bly, not even half of the BCSPs in Spain use 
brochures. Further, decision aids help women 
gain more knowledge than brochures(24). Such 
tools also seem to increase the percentage 
of women reaching an informed decision(25), 
Ballesteros-Peña et al.
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although it is true that an approach focused on 
maximizing the quantity and quality of infor-
mation should be based on the combination 
of different information formats available. On 
the other hand, it does seem that providing 
adequate information would not lead to ad-
verse effects such as increases in the levels of 
concern about cancer or negative emotions(20).
The next question that we should be asking 
ourselves is whether users received sufficient 
information (taking into account that they 
do not only obtain information from scree-
ning programs but also from other sources 
such as awareness campaigns, advertisement 
and news in the media, etc.) for the decision 
of whether to participate to be taken freely. 
This is considered a prerequisite for infor-
med decision making, although information 
alone does not ensure that decisions are in-
dependent; for this, it is necessary to confirm 
that the information has been digested and 
understood, and that the final choice is made 
freely and finally reflects personal values and 
preferences(26,27). Indeed, it is one thing that 
information is available and quite another 
that it is understood, there being sociode-
mographic and cultural factors that seem to 
bridge this gap(28). On the other hand, people 
take decisions based not only on facts but also 
on values, beliefs and personal preferences, 
and this is reflected in the fact that many peo-
ple feel overwhelmed by statistics and prefer 
the advice of other people (close survivors of 
cancer, health professionals) before making 
a decision(20,29,30). Further, asking for advice 
should not be interpreted as implicitly giving 
permission to others to make the final deci-
sion, since it does not mean that person asking 
for the advice is not able or does not wish in 
the end to make an independent decision(31). 
Finally, it can be considered striking that 
contradictory information was provided in 
material from different autonomous regions 
within Spain, notably, concerning breast self-
examination, a practice that was encouraged 
in some programs but recommended against 
in others (on the grounds that according to the 
current scientific evidence it poses more risks 
than benefits), as this may lead to confusion 
making decisions more difficult and undermi-
ning the trustworthiness of the information.
The aforementioned findings have led 
some countries (such as France, Switzerland 
and the United Kingdom) to consider alterna-
tives to the current model of decision making, 
such as shared decision making(8). Unlike 
the pattern of decision making prevailing in 
Spain, in which there is a one-way transfer 
of information, without the participation of 
users in the process or provision of perso-
nalized information, in shared decision ma-
king options are presented and information is 
personalized, the concerns and goals of each 
person are assessed and there is help to ensu-
re decisions are in line with personal levels 
of risk, values and preferences. This process 
(the implementation of which is not without a 
certain degree of complexity) should be sup-
ported by infographics or pictograms visually 
illustrating the main results (preferably in ab-
solute terms), vignettes, videos and other aids 
to support clinical decision making, as well as 
the organization of face-to-face information 
sessions. Interventions based on this model of 
shared decision making have shown to impro-
ve people’s level of knowledge regarding the 
usefulness of screening and reduce decisional 
conflict, without influencing the quality of the 
decision or the final objective(32). In our stu-
dy, we found that only four BCSPs included 
pictograms in the materials they provide and 
very few provide absolute numbers on the be-
nefits or risks of screening.
The main limitation of our study lies in 
the difficulty of accessing all the informa-
tion available in all the autonomous regions 
across Spain. Despite our efforts to obtain all 
the up-to-date materials, we may not have co-
llected all the information available. Never-
theless, given the wide variety of documents 
retrieved, the sample used in this study can be 
considered representative of the current status 
of the official written information concerning 
BCSPs in our country. Another limitation of 
our study is that we analyzed the information 
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dichotomously (provided or not), but we did 
not analyze its quality or whether informed 
decision making is encouraged, despite tools 
to assess the quality of the decision support 
systems now being available(33), nor did we 
assess the way in which information was pre-
sented, when this may be important. It has 
been demonstrated that individuals’ decisions 
are influenced by the framing of information, 
in particular, the presenting of information 
in a schematic way seen to be equivalent to 
certain values or ideas seeking to promote 
particular interpretations or motivations and 
discourage others(26). Indeed, the potential 
power of framing can be seen by comparing 
which data are and are not given: one exam-
ple could be underlining the prevalence of 
breast cancer (given by nearly three-quarters 
of the BCSPs in our study) but not the esti-
mated lifelong cumulative risk of developing 
the disease (given by considerably less than 
half of programs), which could magnify the 
nature of the problem and lead to a higher 
rate of participation in the screening. 
Future studies should, therefore, assess 
not only the information itself but also the 
influence of different focuses in its provi-
sion on decisions and on how freely they are 
taken. Further, greater efforts should be made 
in the framework of the National Health Sys-
tem to provide the population with the most 
complete and balanced information possible. 
Finally, a consensus should be reached on the 
content of the materials for the target popu-
lation, as well as the channel and format for 
presenting it, based on models and tools that 
have been shown to increase user knowled-
ge and favor informed decision making, and 
efforts should be made to strengthen mecha-
nisms for monitoring and comparing infor-
mation resources between BCSPs across the 
country.
The content of official written information 
on BCSPs based on mammograms provided 
in Spain varies between programs and should 
be improved if we want to encourage women 
to acquire knowledge and make informed 
decisions. More efforts should be made to 
provide information based on the best avai-
lable evidence, using simple terms and well-
balanced data with absolute numbers on the 
benefits and risks of screening presented in 
the form of pictograms, without omitting in-
formation related to the characteristics of the 
disease, the functioning of the program and 
related tests, and the interpretation of results, 
as well as their emotional impact.
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